|
Abdul-Hassan H, El-Tahan E, Massoud E, Gomaa R (1990). Bacteriophage therapy of pseudomonas burn wound sepsis. Ann. Medit. Burn Club 3:262-264.
|
|
|
|
Abedon S, Kuhl S, Blasdel B, Kutter E (2011). Phage treatment of human infections. Bacteriophage1:66-85.
|
|
|
|
Abedon ST (2009). Phage evolution and ecology. Adv. Appl. Microbiol.67:1-45.
Crossref
|
|
|
|
Abhilash M, Vidya A, Jagadevi T (2008). Bacteriophage therapy: a war against antibiotic resistant bacteria. Internet J. Altern. Med. 7:e17744
|
|
|
|
Acar J, Rostel B (2001). Antimicrobial resistance: an overview. Rev Sci. Technol. 20:797-810.
Crossref
|
|
|
|
Adhya S, Merril CR, Biswas B (2014). Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold spring harb. Perspect. Med. 4:a012518.
Crossref
|
|
|
|
Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A, Nickho H (2016). Phage display as a promising approach forvaccine development. J. Biomed. Sci. 23:66-84.
Crossref
|
|
|
|
Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F (2012). Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio3: e00029-12.
|
|
|
|
Asheshov IN, Wilson J, Topley WWC (1934). The effect of an anti-VI bacteriophage on typhoid infection in mice. Lancet 1:319-320.
|
|
|
|
Babalova EG, Katsitadze KT, Sakvarelidze LA, Imnaishvili N, Sharashidze TG, Badashvili VA (1968). Preventive value of dried dysentery bacteriophage. Zh. Mikrobiol. Epidemiol. Immunobiol. 45:143-145.
|
|
|
|
Bao HD, Zhang PY, Zhang H, Zhou Y, Zhang LL, Wang R (2015). Bio-control of Salmonella enteritidis in foods using bacteriophages. Viruses 7:4836-4853.
Crossref
|
|
|
|
Bigwood T, Hudson JA, Billington C, Carey-Smith GV, Heinemann JA (2008). Phage inactivation of foodborne pathogens on cooked and raw meat. Food Microbiol. 25:400-406.
Crossref
|
|
|
|
Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin–resistant Enterococcus faecium. Infect. Immun. 70:204-210.
Crossref
|
|
|
|
Boratynski J, Syper D, Weber-Dabrowska B, Lusiak-Szelachowska M, Pozniak G, Gorski A (2004). Preparation of endotoxin-free bacteriophages. Cell Mol. Biol. Lett. 9:253-259.
|
|
|
|
Borysowski J, Weber-DÄ…browska B, Górski AJ (2006). Current status and perspectives of phage therapy. Adv. Clin. Exp. Med.15:575-580.
|
|
|
|
Bren L (2007). Bacteria-eating virus approved as food additive. FDA Consum. 41:20-22.
|
|
|
|
Broudy TB, Fischetti VA (2003). In vivo lysogenic conversion of Tox(-) Streptococcus pyogenes to Tox(+) with lysogenic streptococci or free phage. Infect. Immun. 71:3782-3786.
Crossref
|
|
|
|
Brussow H (2012). What is needed for phage therapy to become a reality in Western medicine? Virol. 434:138-142.
Crossref
|
|
|
|
Bueno E, García P, Martínez B, Rodríguez A (2012). Phage inactivation of S. aureus in fresh and hard-type cheeses. Int. J. Food Microbiol.158:23-27.
Crossref
|
|
|
|
Carlton RM (1999). Phage therapy: past history and future prospects. Arch. Immunol. Ther. Exp. (Warsz). 47:267-274.
|
|
|
|
Carvalho CM, Gannon BW, Halfhide DE, Santos SB, Hayes CM, Roe JM (2010). The in vivo efficacy of two administration routes of a phage cocktail to reduce numbers of Campylobacter coli and Campylobacter jejuni in chickens. BMC Microbiol. 10:232-242.
Crossref
|
|
|
|
Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE (2016). Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6:26717-26724.
Crossref
|
|
|
|
Cheng Q, Nelson D, Zhu S, Fischetti VA (2005). Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob. Agents Chemother. 49:111-117.
Crossref
|
|
|
|
Chhibber S, Kumari S (2012). Application of therapeutic phages in medicine. In: Bacteriophages, (Kurtböke, I., ed). InTech, Croatia. pp. 140-158.
Crossref
|
|
|
|
Chhibber S, Kaur S, Kumari S (2008). Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 57:1508-1513.
Crossref
|
|
|
|
Cislo M, Dabrowski M, Weber-Dabrowska B, Woyton A (1987). Bacteriophage treatment of suppurative skin infections. Arch. Immunol. Ther. Exp. (Warsz) 35:175-183.
|
|
|
|
Clark JR, March JB (2004a). Bacterial viruses as human vaccines? Expert Rev. Vaccines 3:463-476.
Crossref
|
|
|
|
Clark JR, March JB (2004b). Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol. Med. Microbiol. 40:21-26.
Crossref
|
|
|
|
Clark JR, March JB (2006). Bacteriophages and biotechnology: Vaccines, gene therapy and antibacterials. Trends Biotechnol. 24: 212-218.
Crossref
|
|
|
|
Clokie MRJ, Kropinski AM (2009). Bacteriophages: Methods and Protocols, Volume 1: Isolation, Characterization, and Interactions. Humana Press, New York.
|
|
|
|
Colom J, Cano-Sarabia M, Otero J, Cortés P, Maspoch D, Llagostera M (2015). Liposome-encapsulated bacteriophages for enhanced oral phage therapy against Salmonella spp. Appl. Environ. Microbiol. 81:4841-4849.
Crossref
|
|
|
|
Corbitt AJ, Bennion N, Forsythe SJ (2000). Adenylate kinase amplification of ATP bioluminescence for hygiene monitoring in the food and beverage industry. Lett. Appl. Microbiol. 30:443-447.
Crossref
|
|
|
|
d'Herelle F (1926). The Bacteriophage and Its Behavior. Williams and Wilkins, Baltimore, Maryland.
Crossref
|
|
|
|
Davis BM, Waldor MK (2003). Filamentous phages linkedto virulence of Vibrio cholerae. Curr. Opin. Microbiol. 6: 35-42.
Crossref
|
|
|
|
de la Cruz VF, Lal AA, McCutchan TF (1988). Immunogenicity and epitope mapping of foreign sequences via genetically engineered filamentous phage. J. Biol. Chem. 263:4318-4322
|
|
|
|
Dickerson TJ, Kaufmann GF, Janda KD (2005). Bacteriophage-mediated protein delivery into the central nervous system and its application in immunopharmacotherapy. Expert Opin. Biol. Ther. 5:773-781.
Crossref
|
|
|
|
Ding Y, Niu YD, Stanford K, Holley R, McAllister T, Narvaez-Bravo C (2016). Biocontrol of verotoxigenic Escherichia coli in vitro and on Romaine lettuce using lytic phages at different temperatures. Poster presented at: Annual Meeting of IAFP 2016; Jul 31-Aug 3, St. Louis, Missouri. Abstract retrieved at: https://iafp.confex.com/iafp/2016/webprogram/Paper12023.html
|
|
|
|
Edgar R, Friedman N, Molshanski-Mor S, Qimron U (2012). Reversing bacterial resistance to antibiotics by phage mediated delivery of dominant sensitive genes. Appl. Environ. Microbiol.78:744-751.
Crossref
|
|
|
|
El-Shibiny A (2016). Bio-control of E. coli and Salmonella in foods using bacteriophage to improve food safety. World J. Dairy Food Sci.11:150-155.
|
|
|
|
El-Shibiny A, Scott A, Timms A, Metawea Y, Connerton P, Connerton I (2009). Application of a group II Campylobacter bacteriophage to reduce strains of Campylobacter jejuni and Campylobacter coli colonizing broiler chickens. J. Food Protect. 724):733-740.
|
|
|
|
Fan H, Tong Y (2012). Potential duel-use of bacteriophage related technologies in bioterrorism and biodefense. J. Bioterr. Biodef. 3:121-124.
Crossref
|
|
|
|
Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L (2005). The potential of phage display virions expressing malignant tumor speciï¬c antigen MAGE-A1 epitope in murine model. Vaccine 23:4860-4866.
Crossref
|
|
|
|
Favrin SJ, Jassim SA, Griffiths MW (2003). Application of a novel immunomagnetic separationbacteriophage assay for the detection of Salmonella enteritidis and Escherichia coli O157:H7 in food. Int. J. Food Microbiol. 85:63-71.
Crossref
|
|
|
|
Fischetti VA (2011). Exploiting what phage have evolved to control gram-positive pathogens. Bacteriophage 1:188-194.
Crossref
|
|
|
|
Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S (2016). Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J. Wound Care 7:S27-33.
Crossref
|
|
|
|
Funatsu T, Taniyama T, Tajima T, Tadakuma H, Namiki H (2002). Rapid and sensitive detection method of a bacterium by using a GFP reporter phage. Microbiol. Immunol. 46:365-369.
Crossref
|
|
|
|
Galarce NE, Bravo JL, Robeson JP, Borie CF (2014). Bacteriophage cocktail reduces Salmonella enterica serovars enteritidis counts in raw and smoked salmon tissues. Rev. Argent Microbiol. 46:333-337.
Crossref
|
|
|
|
García P, Martínez B, Obeso JM, Rodríguez A (2008). Bacteriophages and their application in food safety. Lett. Appl. Microbiol. 47:479-485.
Crossref
|
|
|
|
Garcia P, Madera C, Martinez B, Rodriguez A (2007). Biocontrol of S. aureus in curd manufacturing processes using bacteriophages. Int. Dairy J. 17: 1232-1239.
Crossref
|
|
|
|
Garcia P, Martinez B, Rodriguez L, Rodriguez A (2010). Synergy between the phage endolysin LysH5 and nisin to kill Staphylococcus aureus in pasteurized milk. Int. J. Food. Microbiol. 141:151-155.
Crossref
|
|
|
|
Geier M, Frigg ME, Merril C (1973). Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246:221-222.
Crossref
|
|
|
|
Goodridge L, Abedon ST (2003). Bacteriophage biocontrol and bioprocessing: Application of phage therapy in industry. SIM News 53:254-262.
|
|
|
|
Goodridge L, Chen J, Griffiths M (1999). Development and characterization of a fluorescent-bacteriophage assay for detection of Escherichia coli O157: H7. Appl. Environ. Microbiol. 65:1397-1404.
|
|
|
|
Grandgirard D, Loeffler JM, Fischetti VA, Leib SL (2008). Phage lytic enzyme cpl-1 for antibacterial therapy in experimental Pneumococcal meningitis. J. Infect. Dis.197:1519-1522.
Crossref
|
|
|
|
Guenther S, Huwyler D, Richard S, Loessner MJ (2009). Virulent bacteriophage for efï¬cient biocontrol of Listeria monocytogenes in ready-to-eat foods. Appl. Environ. Microbiol. 75:93-100.
Crossref
|
|
|
|
Gupta A, Onda M, Pastan I, Adhya S, Chaudhary VK (2003). High-density functional display of proteins on bacteriophage λ. J. Mol. Biol. 334:241-254.
Crossref
|
|
|
|
Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U (2004). Therapy of experimental pseudomonas infections with a non replicating genetically modiï¬ed phage. Antimicrob. Agents Chemother. 48:3817-3822.
Crossref
|
|
|
|
Hatfull GF, Hendrix RW (2011). Bacteriophages and their genomes. Curr. Opin. Virol. 1:298-303.
Crossref
|
Hausler T (2006). Viruses vs Superbugs. A Solution to the Antibiotic Crisis? Macmillan.
Crossref
|
|
|
|
Hayes S, Gamage LN, Hayes C (2010). Dual expression system for assembling phage λ display particle vaccine to porcine Circovirus 2 (PCV2). Vaccine 28: 6789-6799.
Crossref
|
|
|
|
|
Hennes KP, Suttle CA (1995). Direct counts of viruses in natural waters and laboratory cultures by epifluorescence microscopy. Limnol. Oceanogr. 40:1050-1055.
Crossref
|
|
|
|
|
Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM (2003). Evaluation of aerosol spray and intramuscular injection of bacteriophage to treat an Escherichia coli respiratory infection. Poult. Sci. 82:1108-1112.
Crossref
|
|
|
|
|
Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N (2011). Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob. Agents Chemother. 55:1358-1365.
Crossref
|
|
|
|
|
Jalasvuori M, Friman VP, Nieminen A, Bamford JK, Buckling A (2011). Bacteriophage selection against a plasmid-encoded sex apparatus leads to the loss of antibiotic-resistance plasmids. Biol. Lett. 7:902-905.
Crossref
|
|
|
|
|
Jamalludeen N, Johnson RP, Shewen PE, Gyles CL (2009). Evaluation of bacteriophages for prevention and treatment of diarrhea due to experimental enterotoxigenic Escherichia coli O149 infection of pigs. Vet. Microbiol. 136:135-141.
Crossref
|
|
|
|
|
Jikia D, Chkhaidze N, Imedashvili E, Mgaloblishvili I, Tsitlanadze G, Katsarava R (2005). The use of a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries exposure to Sr90. Clin. Exp. Dermatol. 30:23-26.
Crossref
|
|
|
|
|
Kaczkowski H, Weber-Dabrowska B, Dabrowski M, Zdrojewicz Z, Cwioro F (1990). Use of bacteriophages in the treatment of chronic bacterial diseases. Wiad. Lek. 43:136-141.
|
|
|
|
|
Katsarava R, Alavidze Z (2004). Polymer blends as biodegradable matrices for preparing biocomposites. U.S. patent 6,703,040. Intralytix, Inc., U.S.A.
|
|
|
|
|
Keary R, McAuliffe O, Ross RP, Hill C, O'Mahony J, Coffey A (2013). Bacteriophages and their endolysins for control of pathogenic bacteria. In: Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education, pp. 1028-1040, (Méndez-Vilas, A. ed). Formatex Research Center, Spain.
|
|
|
|
|
Kishor C, Mishra RR, Saraf SK, Kumar M, Srivastav AK, Nath G (2016). Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Ind. J. Med. Res.143:87-94
Crossref
|
|
|
|
|
Kodikara CP, Crew HH, Stewart GS (1991). Near on-line detection of enteric bacteria using lux recombinant bacteriophage. FEMS Microbiol. Lett. 67:261-265.
Crossref
|
|
|
|
|
Krom RJ, Bhargava P, Lobritz MA, Collins JJ (2015). Engineered phagemids for non-lytic, targeted antibacterial therapies. Nano Lett. 15: 4808-4813.
Crossref
|
|
|
|
|
Kutter E, Sulakvelidze A (2005). ntroduction. In: Bacteriophage: Biology and Application, pp. 1–4, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.
|
|
|
|
|
Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S (2010). Phage therapy in clinical practice: Treatment of human infections. Curr. Pharm. Biotechnol. 11:69-86.
Crossref
|
|
|
|
|
Leszczynski P, Weber-Dabrowska B, Kohutnicka M, Luczak M, Gorski A (2006). Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker- case report. Folia Microbiol. 51:236-238.
Crossref
|
|
|
|
|
Li Q, Shivachandra SB, Leppla SH, Rao VB (2006a). Bacteriophage T4 capsid: A unique platform for efï¬cient surface assembly of macromolecular complexes. J. Mol. Biol. 363:577-588.
Crossref
|
|
|
|
|
Li XH, Tang L, Liu D, Sun HM, Zhou CC, Tan LS (2006b). Antitumor effect of recombinant T7 phage vaccine expressing xenogenic vascular endothelial growth factor on Lewis lung cancer in mice. Ai Zheng 25:1221-1226.
|
|
|
|
|
López-Cuevas O, Castro-del Campo N, Chaidez C (2016). Biocontrol of Salmonella typhimurium growth in tomato surface by bacteriophage P22. Afr. J. Microbiol. Res. 10:528-534.
Crossref
|
|
|
|
|
Lu TK, Koeris MS (2011). The next generation of bacteriophage therapy. Curr. Opin. Microbiol.14:524-531.
Crossref
|
|
|
|
|
March JB, Clark JR, Jepson CD (2004). Genetic immunisation against hepatitis B using whole bacteriophage λ particles. Vaccine 22:1666-1671.
Crossref
|
|
|
|
|
Marinelli LJ, Fitz-Gibbon S, Hayes C, Bowman C, Inkeles M, Loncaric A (2012). Propionibacterium acnes bacteriophages display limited genetic diversity and broad killing activity against bacterial skin isolates.MBio3: e00279-12
Crossref
|
|
|
|
|
Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG Jr., Sulakvelidze A (2002). A novel sustained-release matrix based on biodegradable poly(ester amide)s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J. Dermatol. 41:453-458.
Crossref
|
|
|
|
|
Marti E, Variatza E, Balcázar JL (2014). Bacteriophages as a reservoir of extended-spectrum β-lactamase and fluoroquinolone resistance genes in the environment. Clin. Microbiol. Infect. 20: 0456-0459.
|
|
|
|
|
McAuliffe O, Ross RP, Fitzgerald GF (2007). The new phage biology: From genomics to applications. In:Bacteriophage: Genetics and Molecular Biology, pp. 1-42, (Mc Grath, S. and Van Sindren, D., eds). Caister Academic Press.
|
|
|
|
|
Mendes JJ, Leandro C, Corte-Real S, Barbosa R, Cavaco-Silva P, Melo-Cristino J (2013). Wound healing potential of topical bacteriophage therapy on diabetic cutaneous wounds. Wound Repair Regen. 21:595-603.
Crossref
|
|
|
|
|
Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N (2009). Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE4: e4944.
Crossref
|
|
|
|
|
Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S (1996). Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 93:3188-3192.
Crossref
|
|
|
|
|
Merril CR, Geier MR, Petricciani JC (1971). Bacterial virusgene expression in human cells. Nature 233:398-400.
Crossref
|
|
|
|
|
Merril CR, Scholl D, Adhya S (2006). Phage therapy. In: The Bacteriophages, 2nd edn., (Calendar, R. ed). Oxford University Press, New York. pp. 725-741.
|
|
|
|
|
Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Szufnarowski K (2012). Clinical aspects of phage therapy. Adv. Virus Res. 83:73-121.
Crossref
|
|
|
|
|
Miller RW, Skinner J, Sulakvelidze A, Mathis GF, Hofacre CL (2010). Bacteriophage therapy for control of necrotic enteritis of broiler chickens experimentally infected with Clostridiumperfringens. Avian Dis. 54: 33-40.
Crossref
|
|
|
|
|
Monk AB, Rees CD, Barrow P, Hagens S, Harpe DR (2010). Bacteriophage applications: where are we now? Lett. App. Microbiol. 51:363-369.
Crossref
|
|
|
|
|
Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L (2011). Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One6:e16963.
Crossref
|
|
|
|
|
Nelson D, Loomis L, Fischetti VA (2001). Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl. Acad. Sci. USA 98:4107-4112.
Crossref
|
|
|
|
|
Nixon AE, Sexton D, Ladner RC (2014). Drugs derivedfrom phage display. MAbs 6:73-85.
Crossref
|
|
|
|
|
Orndorff PE (2016). Use of bacteriophage to target bacterial surface structuresrequired for virulence: a systematic search for antibiotic alternatives. Curr. Genet. 62:753-757.
Crossref
|
|
|
|
|
Parracho HM, Burrowes BH, Enright MC, McConville ML, Harper DR (2012). The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6:279-286.
Crossref
|
|
|
|
|
Paschke M (2006). Phage display systems and their applications. Appl. Microbiol. Biotechnol. 70:2-11.
Crossref
|
|
|
|
|
Perepanova TS, Darbeeva OS, Kotliarova GA, Kondrat'eva EM, Maiskaia LM, Malysheva VF (1995). The efï¬cacy of bacteriophage preparations in treating inflammatory urologic diseases. Urol. Nefrol. (Mosk) 5:14-17.
|
|
|
|
|
Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P (2012). Efï¬cacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob. Agents. Chemother. 56: 3568-3575.
Crossref
|
|
|
|
|
Proskurov VA (1970). Use of staphylococcal bacteriophage for therapeutic and preventive purposes. Zh. Mikrobiol. Epidemiol. Immunobiol. 47: 104-107.
|
|
|
|
|
Ramesh V, Fralick JA, Rolfe RD (1999). Prevention of Clostridium difï¬cile induced ileocecitis with bacteriophage. Anaerobe 5:69-78.
Crossref
|
|
|
|
|
Rath D, Amlinger L, Rath A, Lundgren M (2015). The CRISPR-Cas immune system: Biology, mechanisms and applications. Biochimie. 117:119-128.
Crossref
|
|
|
|
|
Rees C, Loessner M (2005). Phage for the detection of pathogenic bacteria. In: Bacteriophage: Biology and Application, pp. 267-284, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.
|
|
|
|
|
Rossi LP, Almeida RC, Lopes LS, Figueiredo AC, Ramos MP, Almeidia PF (2011). Occurrence of Listeria spp. in Brazilian fresh sausage and control of Listeria monocytogenes using bacteriophage P100. Food Control 22: 954-958.
Crossref
|
Sakaguchi Y, Hayashi T, Kurokawa K, Nakayama K, Oshima K, Fujinaga Y (2005). The genome sequence of Clostridium botulinum type C neurotoxin-converting phage and the molecular mechanisms of unstable lysogeny. PNAS102: 17472-17477.
|
|
|
|
Schmelcher M, Powell AM, Becker SC, Camp MJ, Donovan DM (2012). Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl. Environ. Microbiol. 78:2297-2305.
Crossref
|
|
|
|
|
Seed KD (2015). Battling phages: How bacteria defend against viral attack. PLoS Pathogen.11:e1004847.
Crossref
|
|
|
|
|
Segundo N, Hernández E, López O, Torres O (2010). Los bacteriófagos como una alternativa en el tratamiento de enfermedades infecciosas Bacterianas (Fagoterapia). Rev. Mex. Cienc. Farm 41:17-26.
|
|
|
|
|
Sherman M (2008). Bacteriophages: beyond antibiotics. U.S. Pharm.33: 1-12.
|
|
|
|
|
Sidhu, S.S. (2000). Phage display in pharmaceutical biotechnology. Curr. Opin. Biotechnol. 11:610-616.
Crossref
|
|
|
|
|
Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A (1987). Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch. Immunol. Ther. Exp. (Warsz) 35:569-583.
|
|
|
|
|
Smith GP (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Sci. 228:1315-1317.
Crossref
|
|
|
|
|
Smith HW, Huggins MB (1982). Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.
Crossref
|
|
|
|
|
Smith HW, Huggins MB (1983). Effectiveness of phages in treating experimental E. coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol.129: 2659-2675.
Crossref
|
|
|
|
|
Soni KA, Nannapaneni R (2010). Removal of Listeria monocytogenes biofilms with bacteriophage P100. J. Food Prot. 73: 1519-1524.
Crossref
|
|
|
|
|
Spricigo DA, Bardina C, Cortés P, Llagostera M (2013). Use of a bacteriophage cocktail to control Salmonella in food and the food industry. Int. J. Food Microbiol.165:169-174.
Crossref
|
|
|
|
|
Stratmann J, Strommenger B, Stevenson K, Gerlach GF (2002). Development of a peptidemediated capture PCR for detection of Mycobacterium avium subsp paratuberculosis in milk. J. Clin. Microbiol. 40:4244-4250.
Crossref
|
|
|
|
|
Stroj L, Weber-Dabrowska B, Partyka K., Mulczyk M, Wojcik M (1999). Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn. Neurol. Neurochir. Pol. 33:693-698.
|
|
|
|
|
Sulakvelidze A, Kutter E (2005). Bacteriophage therapy in humans. In: Bacteriophage: Biology and Application, pp. 381-436, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.
|
|
|
|
|
Sulakvelidze A, Alavidze Z, Morris JGJ (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-659.
Crossref
|
|
|
|
|
Summers WC (1999). Bacteriophage discovery, Felix d'Herelle and the Origins of Molecular Biology. Yale University Press.
|
|
|
|
|
Summers WC (2005). Bacteriophage research: Early history. In: Bacteriophage: Biology and Application, pp. 5-27, (Kutter, E. and Sulakvelidze, A., eds). CRC Press, Florida.
|
|
|
|
|
Tanji Y, Shimada MT, Yoichi M, Miyanaga K, Hori K, Unno H (2004). Toward rational control of Escherichia coli O157:H7 by a phage cocktail. Appl. Microbiol. Biotechnol. 64:270-274.
Crossref
|
|
|
|
|
Tesfaye W, Melese A, Henok S, Yohannis M (2017). Prevalence and antimicrobial susceptibility profile of Salmonella sp from ready-to-eat foods from catering establishments in Jigjiga City, Ethiopia, Afr. J. Microbiol. Res. 10: 1555-1560.
Crossref
|
|
|
|
|
Tesfaye W, Ketema B, Melese A, Henok S (2015). Prevalence and Antibiotics Resistance Patterns of S. aureus Isolated from Kitchen Sponge's at Jimma Town Food Establishments, South West Ethiopia. Int. J. Res. Stud. Biosci. 3: 63-71.
|
|
|
|
|
Tomat D, Migliore L, Aquili V, Quiberoni A, Balagué C (2013). Phage biocontrol of enteropathogenic and shiga toxin-producing Escherichia coli in meat products. Front. Cell Infect. Microbiol. 3:20-29.
Crossref
|
|
|
|
|
Turnbough CL (2003). Discovery of phage display peptide ligands for species-speciï¬c detection of Bacillus spores. J. Microbiol. Method. 53:263-271.
Crossref
|
|
|
|
|
Verheust C, Pauwels K, Mahillon J, Helinski D, Herman P (2010). Contained use of bacteriophages: risk assessment and biosafety recommendations. Appl. Biosaf. 15:32-44.
Crossref
|
|
|
|
|
Viazis S, Akhtar M, Feirtag J, Diez-Gonzalez F (2011). Reduction of Escherichia coli O157:H7 viability on hard surfaces by treatment with a bacteriophage mixture. Int. J. Food Microbiol. 145:37-42.
Crossref
|
|
|
|
|
Vieira A, Silva YJ, Cunha A, Gomes NC, Ackermann HW, Almeida A (2012). Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments. Eur. J. Clin. Microbiol. Infect. Dis. 31:3241-3249.
Crossref
|
|
|
|
|
Vieu JF (1975). Les bactériophages. Flammarion, Paris. NOT CITED
|
|
|
|
|
Vinodkumar CS, Kalsurmath S, Neelagund YF (2008). Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonasaeruginosa septicemia in mice. Indian. J. Pathol. Microbiol. 5:360-366.
Crossref
|
|
|
|
|
Vinodkumar CS, Neelagund YF, Kalsurmath S (2005). Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae. J. Communicable Dis. 37:18-29.
|
|
|
|
|
Wagenaar JA, van Bergen MA, Mueller MA, Wassenaar TM, Carlton RM (2005) Phage therapy reduces Campylobacter jejuni colonization in broilers. Vet. Microbiol. 109:275-283.
Crossref
|
|
|
|
|
Wall S, Zhang J, Rostagno M, Ebner P (2010). Phage therapy to reduce pre-processing Salmonella infections in market-weight swine. Appl. Environ. Microbiol. 76:48-53.
Crossref
|
|
|
|
|
Wang J, Hu B, Xu M. Yan Q, Liu S, Zhu X (2006a). Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant P. aeruginosa. Int. J. Mol. Med.17:309-317.
Crossref
|
|
|
|
|
Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X (2006b). Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum β-lactamase-producing Escherichia coli bacteremia. Int. J. Mol. Med.17:347-355.
Crossref
|
|
|
|
|
Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y (2007). Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51:446-452.
Crossref
|
|
|
|
|
Weber-Dabrowska B, Mulczyk M, Górski A (2001). Bacteriophage therapy for infections in cancer patients. Clin. Appl. Immunol. Rev. 1:131-134.
Crossref
|
|
|
|
|
Wright A, Hawkins C, Anggard E, Harper D (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34:349-357.
Crossref
|
|
|
|
|
Yen M, Cairns LS, CamillI A (2017). A cocktail of three virulent bacteriophagesprevents Vibrio cholerae infection in animal models. Nat. Commun. 8:14187.
Crossref
|
|
|
|
|
Yosef I, Manor M, Kiro R, Qimron U (2015). Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc. Natl. Acad. Sci. USA. 112:7267-7272.
Crossref
|
|
|
|
|
Zanghi CN, Sapinoro R, Bradel-Tretheway B, Dewhurst S (2007). A tractable method for simultaneous modiï¬cations to the head and tail of bacteriophage λ and its application to enhancing phage-mediated gene delivery. Nucleic Acids Res. 35:e59.
Crossref
|
|
|
|
|
